These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 9863136)
1. Huperzine A (shuangyiping): a promising drug for Alzheimer's disease. Tang XC Zhongguo Yao Li Xue Bao; 1996 Nov; 17(6):481-4. PubMed ID: 9863136 [TBL] [Abstract][Full Text] [Related]
2. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Wang R; Yan H; Tang XC Acta Pharmacol Sin; 2006 Jan; 27(1):1-26. PubMed ID: 16364207 [TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease. Wang R; Tang XC Neurosignals; 2005; 14(1-2):71-82. PubMed ID: 15956816 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Xu SS; Gao ZX; Weng Z; Du ZM; Xu WA; Yang JS; Zhang ML; Tong ZH; Fang YS; Chai XS Zhongguo Yao Li Xue Bao; 1995 Sep; 16(5):391-5. PubMed ID: 8701750 [TBL] [Abstract][Full Text] [Related]
5. Huperzine a as potential treatment of Alzheimer's disease: an assessment on chemistry, pharmacology, and clinical studies. Ha GT; Wong RK; Zhang Y Chem Biodivers; 2011 Jul; 8(7):1189-204. PubMed ID: 21766442 [TBL] [Abstract][Full Text] [Related]
6. Role of huperzine a in the treatment of Alzheimer's disease. Desilets AR; Gickas JJ; Dunican KC Ann Pharmacother; 2009 Mar; 43(3):514-8. PubMed ID: 19240260 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. Bores GM; Huger FP; Petko W; Mutlib AE; Camacho F; Rush DK; Selk DE; Wolf V; Kosley RW; Davis L; Vargas HM J Pharmacol Exp Ther; 1996 May; 277(2):728-38. PubMed ID: 8627552 [TBL] [Abstract][Full Text] [Related]
8. Huperzine A from Huperzia species--an ethnopharmacolgical review. Ma X; Tan C; Zhu D; Gang DR; Xiao P J Ethnopharmacol; 2007 Aug; 113(1):15-34. PubMed ID: 17644292 [TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Zhang HY; Tang XC Trends Pharmacol Sci; 2006 Dec; 27(12):619-25. PubMed ID: 17056129 [TBL] [Abstract][Full Text] [Related]
10. Huperzia quadrifariata and Huperzia reflexa alkaloids inhibit acetylcholinesterase activity in vivo in mice brain. Konrath EL; Neves BM; Passos Cdos S; Lunardi PS; Ortega MG; Cabrera JL; Gonçalves CA; Henriques AT Phytomedicine; 2012 Nov; 19(14):1321-4. PubMed ID: 23022390 [TBL] [Abstract][Full Text] [Related]
11. Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia. Zhang HY; Zheng CY; Yan H; Wang ZF; Tang LL; Gao X; Tang XC Chem Biol Interact; 2008 Sep; 175(1-3):396-402. PubMed ID: 18565502 [TBL] [Abstract][Full Text] [Related]
12. Huperzine A--an interesting anticholinesterase compound from the Chinese herbal medicine. Patocka J Acta Medica (Hradec Kralove); 1998; 41(4):155-7. PubMed ID: 9951045 [TBL] [Abstract][Full Text] [Related]
13. [Facilitation of cholinergic transmission by huperzine A in toad paravertebral ganglia in vitro]. Zhang GB; Wang MY; Zheng JQ; Tang XC Zhongguo Yao Li Xue Bao; 1994 Mar; 15(2):158-61. PubMed ID: 8010112 [TBL] [Abstract][Full Text] [Related]
14. Anticholinesterase activity and identification of huperzine A in three Mexican lycopods: Huperzia cuernavacensis, Huperzia dichotoma and Huperzia linifolia (Lycopodiaceae). García MV; Poser GLV; Apel M; Tlatilpa RC; Mendoza-Ruiz A; Villarreal ML; Henriques AT; Taketa AC Pak J Pharm Sci; 2017 Jan; 30(1 Suppl):235-239. PubMed ID: 28625948 [TBL] [Abstract][Full Text] [Related]
15. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission. Duysen EG; Li B; Darvesh S; Lockridge O Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517 [TBL] [Abstract][Full Text] [Related]
16. [Huperzine a: an acetylcholinesterase inhibitor with high pharmacological potential]. Pilotaz F; Masson P Ann Pharm Fr; 1999 Sep; 57(5):363-73. PubMed ID: 10520506 [TBL] [Abstract][Full Text] [Related]
17. Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease. Bai DL; Tang XC; He XC Curr Med Chem; 2000 Mar; 7(3):355-74. PubMed ID: 10637369 [TBL] [Abstract][Full Text] [Related]
18. An update on huperzine A as a treatment for Alzheimer's disease. Little JT; Walsh S; Aisen PS Expert Opin Investig Drugs; 2008 Feb; 17(2):209-15. PubMed ID: 18230054 [TBL] [Abstract][Full Text] [Related]
19. Effects of a memory enhancing peptide on cognitive abilities of brain-lesioned mice: additivity with huperzine A and relative potency to tacrine. Xu Z; Zheng H; Law SL; Dong So D; Han Y; Xue H J Pept Sci; 2006 Jan; 12(1):72-8. PubMed ID: 15942937 [TBL] [Abstract][Full Text] [Related]
20. Effects of synthetic (-)-huperzine A on cholinesterase activities and mouse water maze performance. Liu J; Zhang HY; Tang XC; Wang B; He XC; Bai DL Zhongguo Yao Li Xue Bao; 1998 Sep; 19(5):413-6. PubMed ID: 10375798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]